Navigation Links
Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
Date:1/6/2014

SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the J.P. Morgan 2014 Healthcare Conference in San Francisco. The presentation is scheduled for Tuesday, January 14 at 11:30 a.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®. Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for Contrave is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company has submitted applications for marketing authorization in the United States and Europe, with potential approvals in 2014. If approved, North American partner Takeda Pharmaceuticals will commercialize Contrave in the United States. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com. Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
2. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
3. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
4. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
7. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
8. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
9. Orexigen Therapeutics to Present at Upcoming Conferences
10. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
11. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... OHAUS Corporation, a ... launch of its new line of Heavy-Duty Orbital Shakers today. , Eight New ... digital) for laboratory applications. These shakers are ideal for load capacities from ...
(Date:7/17/2017)... ... July 17, 2017 , ... Panitch ... recently participated in the BiG (Biomedical Innovation Group) annual meeting in China. , ... CAR-T (chimeric antigen receptor T-cell) therapy, a rapidly developing highly personalized anti-cancer technology ...
(Date:7/17/2017)... , ... July 17, 2017 , ... ... its long-standing innovation strategy. A website (openinnovation.pioneer.com) dedicated to connecting third-party ... areas – trait discovery, plant breeding, enabling technologies, biologicals and digital solutions. , ...
(Date:7/16/2017)... ... July 16, 2017 , ... OHAUS ... announced the launch of its new line of Extreme Environment Shakers today. , ... require CO2 and humidity for optimal cell growth such as cell cultures, solubility ...
Breaking Biology Technology:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):